Intercell´s clinical data on Japanese Encephalitis vaccine published in "The Lancet"

Intercell´s (ICLL) Phase III clinical trial results on its
investigational Japanese Encephalitis vaccine have been published in
the renowned medical journal “The Lancet” The article is the first
publication describing the full clinical data to date on Intercell´s
vaccine against Japanese Encephalitis The publication details
significant safety and immunogenicity results on the ICLL vaccine,
which represents an innovative approach against a disease with a high
degree of unmet medical need

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

research

Wien (euro adhoc) - Vienna (Austria), December 3, 2007 - Intercell
(VSE: ICLL) is pleased to announce the acceptance of a scientific
article about its investigational Japanese Encephalitis vaccine by
the internationally-renowned scientific and medical journal "The
Lancet".

With over 3 billion people living in endemic areas, Japanese
Encephalitis, a mosquito-borne flaviviral infection, is the leading
cause of childhood encephalitis and viral encephalitis in Asia.
Japanese Encephalitis represents a clear threat to travellers and
military personnel from industrialized countries visiting endemic
areas. The disease is usually severe, resulting in residual
neuropsychiatric sequelae in up to 50% of cases and a fatal outcome
in about 25% of all cases. No treatment is currently available, only
vaccination effectively prevents the disease. Intercell´s innovative
investigational vaccine, which is planned to enter global markets in
2008, is a purified, inactivated product for active immunization
against viral infections of Japanese Encephalitis.

In a recently concluded Phase III non-inferiority trial, Intercell´s
investigational Japanese Encephalitis vaccine demonstrated

» Immunogenicity against Japanese Encephalitis comparable to that of
the U.S. licensed product, JE-VAX®

» An overall clinical safety profile similar to placebo combined with
an excellent local tolerability profile

Intercell´s innovative investigational vaccine, which is manufactured
in the company´s proprietary manufacturing facility in Scotland, is
prepared using tissue culture rather than live organisms and does not
contain stabilizers such as gelatin or preservatives in its
formulation.

The article published in "The Lancet" reports of the detailed
findings in a multicenter, multinational, observer-blinded randomized
controlled Phase III non-inferiority study. The paper was written
under the lead of Intercell´s Vice President of Clinical Development
& Medical Officer, Dr. Erich Tauber, in cooperation with scientists
from the Medical University of Vienna, Austria and University of
Washington, Seattle, USA as well as the Medical University Innsbruck,
Austria.

"This publication on our vaccine means that Intercell´s approach and
the data of our study have been peer-reviewed by highly-ranked
independent scientific and medical experts, who came to the
conclusion that our innovative vaccine, if approved, will meet a
major medical need," stated Alexander von Gabain, Chief Scientific
Officer of Intercell AG. He added: "It is a valuable appreciation of
our scientific work that our data has been published in The Lancet,
which is one of the world´s leading medical journals."

"The Lancet", which first appeared in the year 1823, is an
independent and authoritative voice in global medicine that seeks to
publish high-quality clinical trials that will alter medical
practice. "The Lancet" delivers in-depth knowledge in key medical
disciplines. (www.thelancet.com)

end of announcement euro adhoc 03.12.2007 08:35:00
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market